An official website of the United States government
Study of NXP900 With Osimertinib in Subjects With Advanced, EGFR-Mutated Non-Small Cell Lung Cancer
Trial Status: active
This is a multi-center, open label, Phase 1b study of NXP900 in combination with
osimertinib in subjects with advanced, progressing, EGFR-mutated non-small cell lung
cancer (NSCLC)
Inclusion Criteria
Provide written informed consent.
18 years old or older.
Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.
Unresectable, metastatic or locally advanced EGFR-mutated NSCLC.
Prior treatment with osimertinib as first or second line, as single agent or in combination with chemotherapy, in the metastatic or locally advanced setting.
Exclusion Criteria
Subject's cancer has a known oncogenic driver alteration other than EGFR.
Known EGFR mutations that cause resistance to osimertinib
Known human epidermal growth factor receptor 2 (HER2) overexpression
Any contraindications to treatment with osimertinib
Study sponsor and potential other locations can be found on ClinicalTrials.gov for NCT07315113.
